Relmada Up 6% On Results From Phase 3 REL-1017 Study : vimarsana.com

Relmada Therapeutics, Inc. (RLMD) saw a 6% increase in share value on Monday. This was due to the announcement of efficacy and safety results from their Phase 3 study (Study REL-1017-310) of REL-1017 in patients with Major Depressive Disorder (MDD).

Related Keywords

, Nasdaq , Relmada Therapeutics Inc , Relmada Therapeutics , Major Depressive Disorder , Phase 3 , Lmd , El 1017 ,